New therapeutic target for asthma, other lung disorders identified
April 18th, 2011 - 4:37 pm ICT by ANILondon, April 18 (ANI): A researcher has discovered a molecule’s previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, chronic obstructive pulmonary disease (COPD) and several other lung conditions.
La Jolla Institute for Allergy and Immunology researcher Michael Croft showed that blocking LIGHT’s interactions with its two receptors significantly inhibited the process of airway remodeling in mouse models of chronic asthma.
Airway remodeling refers to inflammation-fueled structural changes in the lungs, including fibrosis, which can occur over time and result in declining lung function that strongly contributes to conditions such as COPD, chronic asthma, and several other respiratory disorders.
The finding marks Croft’s second major discovery with therapeutic potential for asthma.
His previous finding, of a novel molecular mechanism driving lung inflammation, is the basis for a potential asthma treatment now in Phase II human clinical trials.
Current therapies for asthma and COPD primarily include corticosteroids, bronchodilators, and leukotriene antagonists, but these are thought to have little impact, if any, on airway remodeling, said Croft.
Croft said emerging data on the role of the tumor necrosis factor (TNF) super family of molecules in fueling inflammatory diseases, including his own finding on OX40 Ligand and its receptor’s action in triggering inflammation in asthma, prompted him to take a close look at fellow TNF molecule, LIGHT.
“We hypothesized that LIGHT might be involved in driving aspects of lung inflammation or have a role in lung dysfunction that was different than our previous findings on OX40L,” he said.
“As we were undertaking our studies, a report found that increased sputum LIGHT levels in people with asthma correlated with decreased lung function, which was in line with our thinking,” he added.
Using two mouse models of chronic asthma and a therapeutic blocking strategy, Croft said he and his team “demonstrated a direct role for LIGHT in promoting and controlling the extent of remodeling in the lung.”
The study is detailed in the prestigious journal, Nature Medicine. (ANI)
- Protein shows promise in treating smoker's diseases - Jan 16, 2012
- Bitter tasting substances 'found to work better than drugs to treat asthma' - Oct 25, 2010
- Novel finding could lead to new therapies for asthma, COPD - Jan 28, 2011
- Kids with severe asthma at increased risk of developing COPD as adults - May 17, 2010
- Re-engineered toxins can treat asthma, arthritis - Jan 02, 2012
- Asthma patients should stay away from high-fat meals - May 17, 2010
- Estrogen may reduce airway constriction in asthmatic women - May 17, 2010
- Four novel biomarkers that may help diagnose asthma, COPD identified - Mar 12, 2011
- Cigarette smoking ups production of mucus in patients with bronchitis - Feb 18, 2011
- New discovery may lead to improved therapies for lung disease - Sep 16, 2009
- Key mechanism of childhood respiratory disease identified - Mar 08, 2011
- Enzyme essential for healthy lung development discovered - Mar 30, 2011
- Potential therapeutic targets for lung diseases discovered - Dec 14, 2009
- Cigarette smoke may cause inflammation through a new chemical pathway - Sep 03, 2010
- Scientists illuminate cell pathway key to insulin resistance in type 2 diabetes - Feb 25, 2011
Tags: allergy and immunology, asthma treatment, bronchodilators, chronic asthma, chronic obstructive pulmonary disease, corticosteroids, inflammatory diseases, la jolla institute for allergy and immunology, leukotriene antagonists, lung conditions, lung disorders, lung function, lung inflammation, michael croft, molecular mechanism, mouse models, obstructive pulmonary disease, respiratory disorders, therapeutic target, tumor necrosis factor